Methodology & Data Analysis

This report has been prepared by H/Advisors Public Affairs within Havas Group. The insights and analysis has been generated through information gathered by direct engagement and interviews with over 25 European stakeholders during the period December 2022 - February 2023. The stakeholders included MEPs, journalists, health policy advisors from EU-based trade associations, and international patient groups.

The interviews focused on EU healthcare policy in general and specifically on views of the EU pharmaceutical package of legislation currently under revision. In the context of the legislative review, particular focus was placed on the intellectual property incentives framework and how it could address patient access barriers and unmet needs in areas such as rare diseases and medicines for children.

H/Advisors Public Affairs has also reviewed the recently leaked internally circulated version of thepharmaceuticalpackageandhasconsidered it in the context of overall direction of travel and recommendations for engagement in this report.